Patents Assigned to REPRISE PHARMACEUTICALS, INC.
  • Patent number: 11376229
    Abstract: The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: July 5, 2022
    Assignee: REPRISE PHARMACEUTICALS, INC.
    Inventors: Manuel Friese, Benjamin Schattling, Karin Steinbach, Marc Freichel, Veit Flockerzi, Rudi Vennekens, Doron Merkler